WO2010044637A3 - 디펩티딜펩티다아제-ⅳ의 활성을 저해하는 화합물 및 다른 항당뇨 또는 항비만 약물을 유효성분으로 함유하는 당뇨 또는 비만의 예방 및 치료용 약학적 조성물 - Google Patents

디펩티딜펩티다아제-ⅳ의 활성을 저해하는 화합물 및 다른 항당뇨 또는 항비만 약물을 유효성분으로 함유하는 당뇨 또는 비만의 예방 및 치료용 약학적 조성물 Download PDF

Info

Publication number
WO2010044637A3
WO2010044637A3 PCT/KR2009/005970 KR2009005970W WO2010044637A3 WO 2010044637 A3 WO2010044637 A3 WO 2010044637A3 KR 2009005970 W KR2009005970 W KR 2009005970W WO 2010044637 A3 WO2010044637 A3 WO 2010044637A3
Authority
WO
WIPO (PCT)
Prior art keywords
obesity
pharmaceutical composition
diabetes
antidiabetic
prevention
Prior art date
Application number
PCT/KR2009/005970
Other languages
English (en)
French (fr)
Other versions
WO2010044637A9 (ko
WO2010044637A2 (ko
Inventor
신창열
최성현
채유나
양은경
안국준
손문호
김흥재
곽우영
민종필
윤태현
김순회
유무희
Original Assignee
동아제약 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES09820787.1T priority Critical patent/ES2656812T3/es
Priority to CA2740570A priority patent/CA2740570C/en
Priority to JP2011532021A priority patent/JP5364168B2/ja
Priority to NZ592567A priority patent/NZ592567A/xx
Application filed by 동아제약 주식회사 filed Critical 동아제약 주식회사
Priority to AU2009304028A priority patent/AU2009304028B2/en
Priority to CN200980151387.8A priority patent/CN102256605B/zh
Priority to US13/124,150 priority patent/US8440669B2/en
Priority to MX2011004064A priority patent/MX2011004064A/es
Priority to EP09820787.1A priority patent/EP2351567B1/en
Priority to BRPI0920351A priority patent/BRPI0920351B8/pt
Publication of WO2010044637A2 publication Critical patent/WO2010044637A2/ko
Publication of WO2010044637A3 publication Critical patent/WO2010044637A3/ko
Publication of WO2010044637A9 publication Critical patent/WO2010044637A9/ko
Priority to IL212330A priority patent/IL212330A/en
Priority to HK12100710.5A priority patent/HK1160031A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

본 발명은 DPP-IV(Dipeptidyl Peptidase-IV) 저해활성을 갖는 화합물, 이의 약학적으로 허용 가능한 염, 이의 수화물 또는 이의 용매화물과 하나 이상의 다른 항 당뇨 또는 항 비만 약물을 유효성분으로 함유하는 당뇨 또는 비만의 예방 및 치료용 약학적 조성물에 관한 것으로서, 상기 약학적 조성물은 우수한 포도당 내성을 나타내고, 혈중 포도당 농도를 효과적으로 저해하며, 지방 중량을 감소시켜 당뇨병, 비만 등을 예방 및 치료하는데 유용하게 사용될 수 있다.
PCT/KR2009/005970 2008-10-17 2009-10-16 디펩티딜펩티다아제-ⅳ의 활성을 저해하는 화합물 및 다른 항당뇨 또는 항비만 약물을 유효성분으로 함유하는 당뇨 또는 비만의 예방 및 치료용 약학적 조성물 WO2010044637A2 (ko)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CN200980151387.8A CN102256605B (zh) 2008-10-17 2009-10-16 包含抑制二肽基肽酶-iv活性的化合物以及其他抗糖尿病剂或抗肥胖剂作为活性成分的、用于预防和治疗糖尿病或肥胖症的药物组合物
JP2011532021A JP5364168B2 (ja) 2008-10-17 2009-10-16 ジペプチジルペプチダーゼ−ｉｖの活性を阻害する化合物及び異なる抗糖尿または抗肥満薬物を有効成分として含む糖尿または肥満の予防及び治療用薬学的組成物
NZ592567A NZ592567A (en) 2008-10-17 2009-10-16 Pharmaceutical composition for prevention and treatment of diabetes or obesity comprising a compound that inhibits activity of dipeptidyl peptidase-iv, and other antidiabetic or antiobesity agents as active ingredients
MX2011004064A MX2011004064A (es) 2008-10-17 2009-10-16 Composicion farmaceutica para la prevencion y tratamiento de diabetes u obesidad que comprende un compuesto que inhibe la actividad de dipeptidil peptidasa-iv, y otros agentes antidiabeticos o antiobesidad como ingredientes activos.
AU2009304028A AU2009304028B2 (en) 2008-10-17 2009-10-16 Pharmaceutical composition for prevention and treatment of diabetes or obesity comprising a compound that inhibits activity of dipeptidyl peptidase-IV, and other antidiabetic or antiobesity agents as active ingredients
CA2740570A CA2740570C (en) 2008-10-17 2009-10-16 Pharmaceutical composition for prevention and treatment of diabetes or obesity comprising a compound that inhibits activity of dipeptidyl peptidase-iv, and other antidiabetic or antiobesity agents as active ingredients
US13/124,150 US8440669B2 (en) 2008-10-17 2009-10-16 Pharmaceutical composition for prevention and treatment of diabetes or obesity comprising a compound that inhibits activity of dipeptidyl peptidase-IV, and other antidiabetic or antiobesity agents as active ingredients
ES09820787.1T ES2656812T3 (es) 2008-10-17 2009-10-16 Composición farmacéutica para la prevención y el tratamiento de la diabetes u obesidad que comprende un compuesto que inhibe la actividad de dipeptidil peptidasa-IV y otros agentes antidiabéticos o antiobesidad como ingredientes activos
EP09820787.1A EP2351567B1 (en) 2008-10-17 2009-10-16 Pharmaceutical composition for prevention and treatment of diabetes or obesity comprising a compound that inhibits activity of dipeptidyl peptidase-iv, and other antidiabetic or antiobesity agents as active ingredients
BRPI0920351A BRPI0920351B8 (pt) 2008-10-17 2009-10-16 composição farmacêutica para prevenção e tratamento de diabetes ou obesidade
IL212330A IL212330A (en) 2008-10-17 2011-04-14 Pharmaceuticals for the prevention and treatment of diabetes or obesity containing a compound that inhibits dipeptidyl peptidase-iv activity and other anti-diabetic or obesity agents as active ingredients
HK12100710.5A HK1160031A1 (en) 2008-10-17 2012-01-20 Pharmaceutical composition for prevention and treatment of diabetes or obesity comprising a compound that inhibits activity of dipeptidyl peptidase-iv, and other antidiabetic or antiobesity agents as active ingredients -iv

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2008-0101932 2008-10-17
KR1020080101932A KR101054911B1 (ko) 2008-10-17 2008-10-17 디펩티딜펩티다아제-ⅳ의 활성을 저해하는 화합물 및 다른 항당뇨 또는 항비만 약물을 유효성분으로 함유하는 당뇨 또는 비만의 예방 및 치료용 약학적 조성물

Publications (3)

Publication Number Publication Date
WO2010044637A2 WO2010044637A2 (ko) 2010-04-22
WO2010044637A3 true WO2010044637A3 (ko) 2010-08-19
WO2010044637A9 WO2010044637A9 (ko) 2010-10-07

Family

ID=42107077

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/005970 WO2010044637A2 (ko) 2008-10-17 2009-10-16 디펩티딜펩티다아제-ⅳ의 활성을 저해하는 화합물 및 다른 항당뇨 또는 항비만 약물을 유효성분으로 함유하는 당뇨 또는 비만의 예방 및 치료용 약학적 조성물

Country Status (18)

Country Link
US (1) US8440669B2 (ko)
EP (1) EP2351567B1 (ko)
JP (1) JP5364168B2 (ko)
KR (1) KR101054911B1 (ko)
CN (1) CN102256605B (ko)
AU (1) AU2009304028B2 (ko)
BR (1) BRPI0920351B8 (ko)
CA (1) CA2740570C (ko)
ES (1) ES2656812T3 (ko)
HK (1) HK1160031A1 (ko)
HU (1) HUE036475T2 (ko)
IL (1) IL212330A (ko)
MX (1) MX2011004064A (ko)
NZ (1) NZ592567A (ko)
PT (1) PT2351567T (ko)
RU (1) RU2466727C1 (ko)
TR (1) TR201802120T4 (ko)
WO (1) WO2010044637A2 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103848825B (zh) * 2012-12-03 2017-01-25 中国药科大学 具有α‑葡萄糖苷酶抑制活性的锍糖类天然产物及其衍生物的制备方法及用途
EP3015106B1 (en) * 2013-06-26 2021-08-11 Dong-A ST Co., Ltd. Composition for preventing or treating renal diseases, comprising a dpp-iv inhibitor
CN103599540B (zh) * 2013-11-15 2016-09-14 深圳奥萨医药有限公司 含有格列奈类药物和b族维生素的药物组合物及其用途
CN115109161B (zh) * 2022-06-28 2023-08-11 广东赛尔生物科技有限公司 含有间充质干细胞的减肥药物组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030019440A (ko) * 2000-06-19 2003-03-06 스미스클라인비이참피이엘시이 진성 당뇨병 치료를 위한 디펩티틸 펩티다제 ｉｖ 억제제및 다른 항당뇨병제의 병용제

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
UA74912C2 (en) * 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US7262207B2 (en) * 2002-09-19 2007-08-28 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
AU2003298596B2 (en) * 2002-10-18 2008-12-18 Merck Sharp & Dohme Corp. Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
ES2311117T3 (es) 2002-12-10 2009-02-01 Novartis Ag Combinacion de un inhibidor de dpp-iv y un compuesto ppar-alfa.
US7205409B2 (en) * 2003-09-04 2007-04-17 Abbott Laboratories Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
ES2585353T3 (es) 2004-05-12 2016-10-05 Synchronoss Technologies, Inc. Sistema de identificación de contactos avanzado
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
CA2606188A1 (en) 2005-05-02 2006-11-09 Merck & Co., Inc. Combination of dipeptidyl peptidase-iv inhibitor and a cannabinoid cb1 receptor antagonist for the treatment of diabetes and obesity
GT200600218A (es) 2005-06-10 2007-03-28 Formulación y proceso de compresión directa
JP2007024960A (ja) 2005-07-12 2007-02-01 Internatl Business Mach Corp <Ibm> システム、プログラムおよび制御方法
JOP20180109A1 (ar) 2005-09-29 2019-01-30 Novartis Ag تركيبة جديدة
JP5165582B2 (ja) * 2005-12-16 2013-03-21 メルク・シャープ・エンド・ドーム・コーポレイション ジペプチジルペプチダーゼ−４インヒビターとメトホルミンとを組み合わせた医薬組成物
MEP7609A (en) 2005-12-28 2011-12-20 Therapeutic agent for diabetes
JP2008031064A (ja) * 2006-07-27 2008-02-14 Astellas Pharma Inc ジアシルピペラジン誘導体
KR101007497B1 (ko) * 2007-04-19 2011-01-12 동아제약주식회사 베타 아미노기를 포함하는 ｄｄｐ－ⅳ 저해제, 이의제조방법 및 이를 유효성분으로 함유하는 당뇨 또는 비만예방 및 치료용 약학적 조성물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030019440A (ko) * 2000-06-19 2003-03-06 스미스클라인비이참피이엘시이 진성 당뇨병 치료를 위한 디펩티틸 펩티다제 ｉｖ 억제제및 다른 항당뇨병제의 병용제

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KIM DOODEOP ET AL.: "Discovery of potent and selective dipeptidyl peptidase IV inhibitors derived from beta-aminoamides bearing subsituted triazolopiperazines", J. MED. CHEM., January 2008 (2008-01-01), pages 589 - 602, XP008139403 *
LIE ET AL.: "Characterization of two cyclic metabolites of sitagliptin", DRUG METABOLISM AND DISPOSITION: THE BIOLOGICAL FATE OF CHEMICALS, vol. 35, no. 4, 2007, pages 521 - 524, XP008139490 *

Also Published As

Publication number Publication date
IL212330A0 (en) 2011-06-30
BRPI0920351A2 (pt) 2016-03-08
KR101054911B1 (ko) 2011-08-05
CA2740570A1 (en) 2010-04-22
EP2351567A4 (en) 2013-12-04
RU2466727C1 (ru) 2012-11-20
BRPI0920351A8 (pt) 2016-10-04
ES2656812T3 (es) 2018-02-28
US20110201624A1 (en) 2011-08-18
BRPI0920351B8 (pt) 2021-05-25
NZ592567A (en) 2012-08-31
JP5364168B2 (ja) 2013-12-11
WO2010044637A9 (ko) 2010-10-07
CN102256605B (zh) 2014-05-07
HUE036475T2 (hu) 2018-07-30
KR20100042786A (ko) 2010-04-27
AU2009304028B2 (en) 2013-05-16
US8440669B2 (en) 2013-05-14
AU2009304028A1 (en) 2010-04-22
PT2351567T (pt) 2018-02-12
JP2012505876A (ja) 2012-03-08
EP2351567B1 (en) 2017-11-22
EP2351567A2 (en) 2011-08-03
TR201802120T4 (en) 2018-03-21
WO2010044637A2 (ko) 2010-04-22
HK1160031A1 (en) 2012-08-10
IL212330A (en) 2015-11-30
CN102256605A (zh) 2011-11-23
CA2740570C (en) 2015-02-03
BRPI0920351B1 (pt) 2020-09-29
MX2011004064A (es) 2011-05-10

Similar Documents

Publication Publication Date Title
EP1756074A4 (en) 1,2,4-OXADIAZOLE DERIVATIVES AS INHIBITORS OF DIPEPTIDYLPEPTIDASE-IV IN THE TREATMENT OR PREVENTION OF DIABETES
WO2010029089A3 (en) Combination therapy for the treatment of diabetes and related conditions
MX2013004699A (es) Combinaciones farmaceuticas para el tratamiento de trastornos metabolicos.
MY160123A (en) Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
EP1761532A4 (en) AMINOCYCLOHEXANES AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV FOR THE TREATMENT OR PREVENTION OF DIABETES
ZA200708304B (en) Dipeptidyl Peptidase-IV inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent
WO2008108957A3 (en) Piperidinyl-piperidine and piperazinyl-piperidine for use in the treatment of diabetes or pain
EP1978804A4 (en) AMINOCYCLOHEXANES USEFUL AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV FOR TREATING OR PREVENTING DIABETES
EP2019677A4 (en) AMINOETETRAHYDROPYRANES AS DIPEPTIDYLPEPTIDASE IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES
WO2006119958A3 (en) Use of flibanserin in the treatment of chronic pain
WO2006127530A3 (en) Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2007126745A3 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
MX2012006744A (es) Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas.
WO2007027651A3 (en) Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-iv (dpp-iv)
ZA201004214B (en) Dipeptidyl peptidase-iv inhibiting compounds,methods of preparing the same,and pharmaceutical compositions containing the same as active agent
WO2007138466A3 (en) Pharmaceutical compositions comprising meloxicam and tramadol combination
WO2006131874A3 (en) Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury
WO2011049327A3 (en) A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof
WO2010044637A3 (ko) 디펩티딜펩티다아제-ⅳ의 활성을 저해하는 화합물 및 다른 항당뇨 또는 항비만 약물을 유효성분으로 함유하는 당뇨 또는 비만의 예방 및 치료용 약학적 조성물
WO2008016640A3 (en) Use of poloxamer for the prevention and/or treatment of heart failure
EA200800338A1 (ru) Профилактика и лечение офтальмологических осложнений диабета
WO2007113243A3 (en) Use of pde 5 inhibitors for the treatment of overactive bladder
WO2007103149A3 (en) Treatment of atherosclerotic disease
WO2009035253A3 (en) Novel use of scoparone
WO2010117170A3 (ko) 화상 손상의 치료 또는 예방용 약학 조성물

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980151387.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09820787

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2740570

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 13124150

Country of ref document: US

Ref document number: 212330

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2011532021

Country of ref document: JP

Ref document number: MX/A/2011/004064

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 805/MUMNP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 592567

Country of ref document: NZ

REEP Request for entry into the european phase

Ref document number: 2009820787

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009820787

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2009304028

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2011119616

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2009304028

Country of ref document: AU

Date of ref document: 20091016

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0920351

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110418